NR5A1 and glioblastoma: The study further indicated that although AP1 and KLAK are targeting molecules in glioblastoma and ELP improves the half-life of PD, the absence of any of these three peptides in a single treatment results in a diminishing therapeutic effect against glioblastoma, as shown in the group treated with PBS, ELP-KLAK and API-ELP.